Editas Medicine Strikes License Deal With Vertex Pharmaceuticals -- Update
14 December 2023 - 4:48AM
Dow Jones News
By Dean Seal
Editas Medicine has agreed to license Vertex Pharmaceuticals its
Cas9 gene editing technology for ex vivo gene editing medicines
targeted at sickle cell disease and beta thalassemia.
The clinical-stage genome editing company said Wednesday that
under the terms of the agreement, Vertex will obtain a
non-exclusive license for the technology in medicines targeting the
BCL11A gene in the fields of sickle cell disease and beta
thalassemia, which includes the cell-based gene therapy
Casgevy.
The deal extends Editas' cash runway into 2026, the company
said.
In a Securities and Exchange Commission filing, Editas said it
would get an upfront cash payment of $50 million as part of the
licensing deal. It is also eligible for an additional $50 million
contingent upfront payment.
The company would also be entitled to license fees between $10
million and $40 million annually, including certain sales-based fee
increases, through 2034, according to the filing.
Editas will have to pay a mid-double-digit percentage of amounts
received from Vertex under the deal to The Broad Institute and the
President and Fellows of Harvard College as it relates to Cas9
technology licensed from them.
Write to Dean Seal at dean.seal@wsj.com
(END) Dow Jones Newswires
December 13, 2023 12:33 ET (17:33 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
Editas Medicine (NASDAQ:EDIT)
Historical Stock Chart
From Oct 2024 to Nov 2024
Editas Medicine (NASDAQ:EDIT)
Historical Stock Chart
From Nov 2023 to Nov 2024
